PTC Therapeutics, Inc.

NasdaqGS:PTCT Voorraadrapport

Marktkapitalisatie: US$3.1b

PTC Therapeutics Beheer

Beheer criteriumcontroles 2/4

PTC Therapeutics' CEO is Matt Klein, appointed in Mar 2023, has a tenure of 1.67 years. total yearly compensation is $8.94M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth $2.12M. The average tenure of the management team and the board of directors is 5.7 years and 9.4 years respectively.

Belangrijke informatie

Matt Klein

Algemeen directeur

US$8.9m

Totale compensatie

Percentage CEO-salaris8.4%
Dienstverband CEO1.7yrs
Eigendom CEO0.07%
Management gemiddelde ambtstermijn5.7yrs
Gemiddelde ambtstermijn bestuur9.4yrs

Recente managementupdates

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28
Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22
Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18
Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27
Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

Analyse CEO-vergoeding

Hoe is Matt Klein's beloning veranderd ten opzichte van PTC Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$480m

Mar 31 2024n/an/a

-US$579m

Dec 31 2023US$9mUS$747k

-US$627m

Sep 30 2023n/an/a

-US$642m

Jun 30 2023n/an/a

-US$618m

Mar 31 2023n/an/a

-US$571m

Dec 31 2022US$5mUS$598k

-US$559m

Compensatie versus markt: Matt's total compensation ($USD8.94M) is above average for companies of similar size in the US market ($USD6.66M).

Compensatie versus inkomsten: Matt's compensation has increased whilst the company is unprofitable.


CEO

Matt Klein (52 yo)

1.7yrs

Tenure

US$8,937,025

Compensatie

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Matthew Klein
CEO & Director1.7yrsUS$8.94m0.068%
$ 2.1m
Stuart Peltz
Co-Founder26.8yrsUS$5.66m0%
$ 0
Allan Jacobson
Co-Founder26.8yrsUS$511.98k0.016%
$ 499.7k
Pierre Gravier
Chief Financial Officer1.3yrsUS$3.01m0.016%
$ 482.8k
Mark Boulding
Executive VP & Chief Legal Officer12.7yrsUS$2.19m0.063%
$ 2.0m
Eric Pauwels
Chief Business Officer9.6yrsUS$2.41m0.026%
$ 798.5k
Lee Golden
Executive VP & Chief Medical Officer4.5yrsUS$2.39m0.019%
$ 601.8k
Christine Utter
Senior VP5.4yrsUS$1.70m0.022%
$ 690.2k
Neil Almstead
Chief Technical Operations Officer5.9yrsUS$2.67m0.054%
$ 1.7m
Linda Carter
Senior VP & Chief Information Officerless than a yeargeen gegevensgeen gegevens
Alex Kane
Investor Relations Officerno datageen gegevensgeen gegevens
Jane Baj
Vice President of Corporate Communicationsno datageen gegevensgeen gegevens

5.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: PTCT's management team is seasoned and experienced (5.7 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Matthew Klein
CEO & Director1.7yrsUS$8.94m0.068%
$ 2.1m
Stuart Peltz
Co-Founder1.7yrsUS$5.66m0%
$ 0
Allan Jacobson
Co-Founder26.8yrsUS$511.98k0.016%
$ 499.7k
Michael Schmertzler
Independent Chairman of the Board23.3yrsUS$816.96k1.95%
$ 60.8m
David Southwell
Independent Director18.9yrsUS$438.98k0.014%
$ 424.9k
Eric Jacobsen
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Emma Reeve
Independent Director5.9yrsUS$441.98k0.0094%
$ 291.4k
Joseph Puglisi
Member of Scientific Advisory Board21yrsgeen gegevensgeen gegevens
Glenn Steele
Independent Director9.4yrsUS$426.98k0.014%
$ 424.9k
Marvin Wickens
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Robert Schneider
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stephanie Okey
Independent Director5.9yrsUS$421.98k0.0076%
$ 237.5k

9.4yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: PTCT's board of directors are considered experienced (9.4 years average tenure).